Abstract
The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (Clin Ther.
Original language | English (US) |
---|---|
Pages (from-to) | 702-710 |
Number of pages | 9 |
Journal | Clinical Therapeutics |
Volume | 43 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2021 |
Keywords
- COVID
- SARS-CoV-2
- baculovirus
- recombinant adenovirus
- vaccines
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology